Clinical trials: Advanced Merkel Cell Carcinoma

Merkel Cell Carcinoma

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

• Completed
• Age: 12 years and older
• Phase 3
• Results posted

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC).

Trial name

NCT03783078

Testing

Pembrolizumab (MK-3475)

Where

22 sites in United States, Australia and 6 more

Volunteers

55 people

Sponsor

Merck Sharp & Dohme LLC